FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hacksell Uli						2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]								5. Relationship (Check all applie X Director)		able)		Owner Owner
(Last) (First) (Middle) 11085 TORREYANA ROAD #100						3. Date of Earliest Transaction (Month/Day/Year) 02/18/2014								X	Officer below)	(give title	Oth belo	er (specify w)
(Street) SAN DII	SAN DIEGO CA 92121			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				ction	2A. E Exec if any	eeme ution		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		I (A) or	5. Amo Securit Benefic Owned		nt of es ally Following	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	of Indirect t Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)		(Instr. 4)
Common Stock 02/18					2014	014					25,000	A	\$6.	95	25	,000	D	
Common Stock 02/18/20					2014)14			G	V	25,000	D	\$()		0	D	
Common Stock 02/18/2					2014)14			G V		25,000	A	\$(\$0		140,549		By Family Trust
Common Stock 02/18/20					2014	14			S ⁽¹⁾		25,000	D	\$24.14	411 ⁽²⁾	115,549		I	By Family Trust
		-	Table I								sposed of , converti				wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Dat Expira (Mont	ation E		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Di Si	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct (or Indir (I) (Inst	Beneficial Ownership ect (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	er				
Stock Option (right to	\$6.95	02/18/2014			M			25,000	(3	3)	03/10/2015	Commo Stock	ⁿ 25,0	00	\$0	25,000) D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2013.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$24.00 to \$24.35 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 3. 25% of the shares subject to the stock option vested and became exercisable on March 11, 2006. The remaining shares vested in equal monthly installments over the following 3 years.

/s/ Glenn F. Baity, Attorney-in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.